Insider Analysis From Morrison & Foerster LLP: China’s Bolar Exemption – Beware of the Uncertainties of Its Reach And Scope (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
By Janet Xiao, Morrison & Foerster LLP, Palo Alto and Michael Vella, Morrison & Foerster LLP, Shangha